details

5,000 runners from all seven continents took part in the 14th NCT Run. Together, the runners from all over the world raised over 50,000 euros in donations, which will benefit innovative applied cancer research projects at the National Center for Tumor Diseases (NCT) in Heidelberg.

The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg.

This year's NCT Run moved people all over the world: From July 11 to 13, 2025, 5,000 participants from the global online community got involved in more than 1,200 locations on all seven continents - for a good cause. Together, they covered an impressive 88,000 kilometers. The detailed run results can be found online at www.nct-lauf.de.

Dirk Jäger, Managing Director of the NCT Heidelberg and Head of Medical Oncology at Heidelberg University Hospital (UKHD), says: "We would like to thank all participants. With their sporting commitment and their willingness to donate, they are making an important contribution to the work at the NCT Heidelberg."

Long-standing main sponsor SAP is rewarding the team spirit and commitment of the participants with a generous donation of 20,000 euros. Further donations from the participants will bring the NCT Run 2025 to a total of over 50,000 euros. The donations will directly benefit innovative applied cancer research projects at the National Center for Tumor Diseases (NCT) Heidelberg.

Stefan Fröhling, Managing Director at the NCT Heidelberg and Head of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: “The fact that the NCT Run once again inspires and connects people on all continents is something very special. The run has many positive effects: It gets people around the world moving, draws attention to pioneering cancer research and raises funds for this important task.”

A picture for the press release is available free of charge at:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/pressemitteilungen/NCT-Lauf_Laufpaar_mit_Hund_NCT_Heidelberg.jpg

Terms of use for images accompanying press releases
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please credit the copyright “NCT Heidelberg”. The image material may only be passed on to third parties after prior consultation with NCT Communications (Tel.: +49 6221 42-1755, E-Mail: martin.staiger@nct-heidelberg.de). Use for commercial purposes is prohibited.

Contact for the press:
Dr. Martin Staiger
National Center for Tumor Diseases (NCT) Heidelberg
Communication and Events
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56-311272
E-mail: martin.staiger(at)nct-heidelberg.de
www.nct-heidelberg.de

The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg. The aim of the NCT Heidelberg is to transfer promising approaches from cancer research into clinical practice as quickly as possible, and thus to benefit patients. This applies to both diagnosis and treatment, in aftercare or prevention. Participation in clinical studies opens up access to innovative therapies. The NCT Heidelberg is thus a leader in transferring new research results from the laboratory to the clinic The NCT Heidelberg, founded in 2004, is part of the NCT with further locations in Berlin, Dresden, SouthWest (Tübingen-Stuttgart/Ulm), WERA (Würzburg, Erlangen, Regensburg, Augsburg) and West (Essen/Cologne).
 

German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

• National Center for Tumor Diseases (NCT, 6 sites)  
• German Cancer Consortium (DKTK, 8 sites)
• Hopp Children's Cancer Center (KiTZ) Heidelberg
• Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
• DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
• National Cancer Prevention Center (jointly with German Cancer Aid) 

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching

Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds.

Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents.

The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.

5,000 runners from all seven continents took part in the 14th NCT Run. Together, the runners from all over the world raised over 50,000 euros in donations, which will benefit innovative applied cancer research projects at the National Center for Tumor Diseases (NCT) in Heidelberg.

The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg.

This year's NCT Run moved people all over the world: From July 11 to 13, 2025, 5,000 participants from the global online community got involved in more than 1,200 locations on all seven continents - for a good cause. Together, they covered an impressive 88,000 kilometers. The detailed run results can be found online at www.nct-lauf.de.

Dirk Jäger, Managing Director of the NCT Heidelberg and Head of Medical Oncology at Heidelberg University Hospital (UKHD), says: "We would like to thank all participants. With their sporting commitment and their willingness to donate, they are making an important contribution to the work at the NCT Heidelberg."

Long-standing main sponsor SAP is rewarding the team spirit and commitment of the participants with a generous donation of 20,000 euros. Further donations from the participants will bring the NCT Run 2025 to a total of over 50,000 euros. The donations will directly benefit innovative applied cancer research projects at the National Center for Tumor Diseases (NCT) Heidelberg.

Stefan Fröhling, Managing Director at the NCT Heidelberg and Head of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: “The fact that the NCT Run once again inspires and connects people on all continents is something very special. The run has many positive effects: It gets people around the world moving, draws attention to pioneering cancer research and raises funds for this important task.”

A picture for the press release is available free of charge at:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/pressemitteilungen/NCT-Lauf_Laufpaar_mit_Hund_NCT_Heidelberg.jpg

Terms of use for images accompanying press releases
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please credit the copyright “NCT Heidelberg”. The image material may only be passed on to third parties after prior consultation with NCT Communications (Tel.: +49 6221 42-1755, E-Mail: martin.staiger@nct-heidelberg.de). Use for commercial purposes is prohibited.

Contact for the press:
Dr. Martin Staiger
National Center for Tumor Diseases (NCT) Heidelberg
Communication and Events
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 56-311272
E-mail: martin.staiger(at)nct-heidelberg.de
www.nct-heidelberg.de

The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg (UKHD), the Heidelberg Medical Faculty of the Heidelberg University and the Thoraxklinik Heidelberg. The aim of the NCT Heidelberg is to transfer promising approaches from cancer research into clinical practice as quickly as possible, and thus to benefit patients. This applies to both diagnosis and treatment, in aftercare or prevention. Participation in clinical studies opens up access to innovative therapies. The NCT Heidelberg is thus a leader in transferring new research results from the laboratory to the clinic The NCT Heidelberg, founded in 2004, is part of the NCT with further locations in Berlin, Dresden, SouthWest (Tübingen-Stuttgart/Ulm), WERA (Würzburg, Erlangen, Regensburg, Augsburg) and West (Essen/Cologne).
 

German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

• National Center for Tumor Diseases (NCT, 6 sites)  
• German Cancer Consortium (DKTK, 8 sites)
• Hopp Children's Cancer Center (KiTZ) Heidelberg
• Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
• DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
• National Cancer Prevention Center (jointly with German Cancer Aid) 

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching

Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds.

Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents.

The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.